IN2014DN03009A - - Google Patents
Info
- Publication number
- IN2014DN03009A IN2014DN03009A IN3009DEN2014A IN2014DN03009A IN 2014DN03009 A IN2014DN03009 A IN 2014DN03009A IN 3009DEN2014 A IN3009DEN2014 A IN 3009DEN2014A IN 2014DN03009 A IN2014DN03009 A IN 2014DN03009A
- Authority
- IN
- India
- Prior art keywords
- hydromorphone
- present technology
- prodrugs
- compositions
- methods
- Prior art date
Links
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 abstract 4
- 229960001410 hydromorphone Drugs 0.000 abstract 4
- 230000003247 decreasing effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- JVCXXTVXDMJSIE-UXLLHSPISA-N (1R,9R,10R)-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-6-ol Chemical compound C1C2=C(O)C=CC=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JVCXXTVXDMJSIE-UXLLHSPISA-N 0.000 abstract 1
- 239000004593 Epoxy Substances 0.000 abstract 1
- -1 aryl carboxylic acids Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161551600P | 2011-10-26 | 2011-10-26 | |
| US201261657201P | 2012-06-08 | 2012-06-08 | |
| PCT/US2012/061813 WO2013063204A1 (en) | 2011-10-26 | 2012-10-25 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydromorphone, prodrugs, methods of making and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN03009A true IN2014DN03009A (en:Method) | 2015-05-08 |
Family
ID=48168468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3009DEN2014 IN2014DN03009A (en:Method) | 2011-10-26 | 2012-10-25 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US8816083B2 (en:Method) |
| EP (1) | EP2771002A4 (en:Method) |
| JP (1) | JP5769889B2 (en:Method) |
| KR (1) | KR101589846B1 (en:Method) |
| CN (2) | CN105749294A (en:Method) |
| AR (1) | AR088551A1 (en:Method) |
| AU (1) | AU2012328837B2 (en:Method) |
| BR (1) | BR112014010099A8 (en:Method) |
| CA (1) | CA2856608C (en:Method) |
| CL (1) | CL2014000995A1 (en:Method) |
| CO (1) | CO7010825A2 (en:Method) |
| HK (2) | HK1197191A1 (en:Method) |
| IL (1) | IL231822A0 (en:Method) |
| IN (1) | IN2014DN03009A (en:Method) |
| MX (1) | MX362857B (en:Method) |
| PH (1) | PH12014500791A1 (en:Method) |
| RU (1) | RU2573388C2 (en:Method) |
| SG (1) | SG11201401856VA (en:Method) |
| WO (1) | WO2013063204A1 (en:Method) |
| ZA (1) | ZA201402339B (en:Method) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA102916C2 (uk) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
| US10849981B2 (en) | 2009-07-02 | 2020-12-01 | KemPham, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
| IN2014DN03009A (en:Method) * | 2011-10-26 | 2015-05-08 | Kempharm Inc | |
| US10626156B2 (en) | 2013-12-06 | 2020-04-21 | Jie Han | Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs |
| GB201417529D0 (en) | 2014-10-03 | 2014-11-19 | Isis Innovation | Beta lactamase inhibitors |
| KR101976101B1 (ko) * | 2014-11-25 | 2019-05-09 | 켐팜 인코포레이티드 | 옥시코돈의 벤조산, 벤조산 유도체 및 헤테로아릴 카르복실산 콘쥬게이트 |
| BR112017011764A2 (pt) * | 2014-12-02 | 2018-07-10 | Kempharm, Inc. | ácido benzóico, derivados de ácido benzóico e conjugados de ácido heteroaril carboxílico de oximorfona, pro-fármacos, métodos e preparação e uso dos mesmos |
| US10226456B2 (en) | 2015-04-27 | 2019-03-12 | 3St Research Llc | Methods and compositions for preventing opioid abuse |
| US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
| US10017519B2 (en) | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
| US9987269B2 (en) | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
| EP3231420A1 (en) * | 2016-02-29 | 2017-10-18 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| EP3210596A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical composition |
| EP3210630A1 (en) | 2016-02-29 | 2017-08-30 | G.L. Pharma GmbH | Abuse-deterrent pharmaceutical compositions |
| US20200038383A1 (en) * | 2016-10-14 | 2020-02-06 | Kempharm, Inc. | Immediate-release abuse deterrent compositions or medicaments for treating pain, add, adhd and other syndromes or disorders |
| SMT202200134T1 (it) | 2018-03-08 | 2022-05-12 | Incyte Corp | Composti di amminopirazindiolo come inibitori di pi3k-y |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| WO2021097531A1 (en) * | 2019-11-22 | 2021-05-27 | Deakin University | Polyionic corrosion inhibitors |
| WO2021097532A1 (en) * | 2019-11-22 | 2021-05-27 | Deakin University | Organic corrosion inhibitors |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4668685A (en) * | 1984-07-05 | 1987-05-26 | E.I. Du Pont De Nemours And Company | Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists |
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| CA2210500A1 (en) * | 1995-01-16 | 1996-07-25 | Commonwealth Scientific And Industrial Research Organisation | Therapeutic compound - fatty acid conjugates |
| DE19602959A1 (de) * | 1995-12-20 | 1997-07-31 | Nycomed Arzneimittel Gmbh | Neue Morphinderivate, Verfahren zu deren Herstellung und deren Verwendung |
| RU2230556C2 (ru) | 1999-10-29 | 2004-06-20 | Эро-Селтик, С.А. | Препаративные формы гидрокодона с контролируемым высвобождением |
| JP4814486B2 (ja) * | 2001-06-05 | 2011-11-16 | シヴィダ・インコーポレイテッド | 持続放出性鎮痛性化合物 |
| US6740641B2 (en) * | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP2006520392A (ja) | 2003-03-13 | 2006-09-07 | コントロールド・ケミカルズ・インコーポレーテッド | 薬物の乱用可能性を低下させ且つ作用持続時間を延長する化合物および方法 |
| NZ546226A (en) | 2003-09-30 | 2009-03-31 | Shire Llc | Oxycodone conjugates for prevention of overdose or abuse |
| US7661226B2 (en) * | 2005-01-11 | 2010-02-16 | Larson Manufacturing Company | Installation method for a storm door |
| EP2007389A2 (en) * | 2006-04-14 | 2008-12-31 | Shire LLC | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
| MX2008014794A (es) | 2006-05-26 | 2009-04-08 | Pharmacofore Inc | Liberacion controlada de opioides fenolicos. |
| WO2008055230A2 (en) | 2006-10-31 | 2008-05-08 | Rebit, Inc. | Automatically shadowing data for a plurality of network-connected computers using a network-attached memory |
| US20120142718A1 (en) * | 2007-02-16 | 2012-06-07 | Jenkins Thomas E | N-17-Alkylated Prodrugs of Opioids |
| WO2009092071A2 (en) | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid and peptide pro-drugs of phenolic analgesics and uses thereof |
| BRPI1015108A2 (pt) | 2009-04-02 | 2016-04-26 | Shire Llc | pró-fármacos de aminoácidos e peptídios ligados a ácido dicarboxílico de opiáceos e seus usos |
| UA102916C2 (uk) * | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Композиція на основі кон'югату гідрокодону з бензойною кислотою, похідними бензойної кислоти або гетероарилкарбоновою кислотою, проліки, спосіб лікування від зловживань |
| WO2011002995A1 (en) * | 2009-07-02 | 2011-01-06 | Kempharm, Inc. | Phenylethanoic acid, phenylpropanoic acid and phenylpropenoic acid conjugates and prodrugs of hydrocodone, methods of making and use thereof |
| WO2011008636A1 (en) | 2009-07-15 | 2011-01-20 | Mallinckrodt Inc. | 3-oxy-hydromorphone derivatives |
| TR201809739T4 (tr) | 2009-07-16 | 2018-07-23 | Mallinckrodt Llc | Toll benzeri reseptör 9 antagonistleri olarak (+)-morfinanlar ve bunların terapötik amaçlı kullanımları. |
| JP2013503862A (ja) | 2009-09-08 | 2013-02-04 | シグネーチャー セラピューティクス，インク． | 酵素切断可能なケトン修飾オピオイドプロドラッグとその任意選択のインヒビターとを含んでなる組成物 |
| PL2593095T3 (pl) | 2010-07-16 | 2019-12-31 | Mallinckrodt Llc | (+)-morfinany jako antagoniści receptora toll-podobnego 9 i ich terapeutyczne zastosowania |
| US8685916B2 (en) | 2011-03-09 | 2014-04-01 | Signature Therapeutics, Inc. | Opioid prodrugs with heterocyclic linkers |
| IN2014DN03009A (en:Method) * | 2011-10-26 | 2015-05-08 | Kempharm Inc |
-
2012
- 2012-10-25 IN IN3009DEN2014 patent/IN2014DN03009A/en unknown
- 2012-10-25 BR BR112014010099A patent/BR112014010099A8/pt not_active Application Discontinuation
- 2012-10-25 CN CN201610210323.2A patent/CN105749294A/zh active Pending
- 2012-10-25 RU RU2014121065/04A patent/RU2573388C2/ru not_active IP Right Cessation
- 2012-10-25 MX MX2014004691A patent/MX362857B/es active IP Right Grant
- 2012-10-25 EP EP12843820.7A patent/EP2771002A4/en not_active Withdrawn
- 2012-10-25 CN CN201280064641.2A patent/CN104136031B/zh not_active Expired - Fee Related
- 2012-10-25 JP JP2014538982A patent/JP5769889B2/ja not_active Expired - Fee Related
- 2012-10-25 PH PH1/2014/500791A patent/PH12014500791A1/en unknown
- 2012-10-25 AU AU2012328837A patent/AU2012328837B2/en not_active Ceased
- 2012-10-25 US US13/660,112 patent/US8816083B2/en active Active
- 2012-10-25 HK HK14110803.0A patent/HK1197191A1/xx unknown
- 2012-10-25 KR KR1020147010696A patent/KR101589846B1/ko not_active Expired - Fee Related
- 2012-10-25 SG SG11201401856VA patent/SG11201401856VA/en unknown
- 2012-10-25 CA CA2856608A patent/CA2856608C/en not_active Expired - Fee Related
- 2012-10-25 WO PCT/US2012/061813 patent/WO2013063204A1/en not_active Ceased
- 2012-10-26 AR ARP120104022A patent/AR088551A1/es unknown
-
2014
- 2014-03-28 ZA ZA2014/02339A patent/ZA201402339B/en unknown
- 2014-03-31 IL IL231822A patent/IL231822A0/en unknown
- 2014-04-17 CL CL2014000995A patent/CL2014000995A1/es unknown
- 2014-04-28 CO CO14089601A patent/CO7010825A2/es unknown
- 2014-07-21 US US14/336,549 patent/US9566343B2/en active Active
-
2016
- 2016-10-04 HK HK16111529.9A patent/HK1223279A1/zh unknown
- 2016-12-30 US US15/395,475 patent/US9849185B2/en active Active
-
2017
- 2017-11-14 US US15/812,823 patent/US10064956B2/en active Active
-
2018
- 2018-08-03 US US16/054,575 patent/US10258696B2/en active Active
-
2019
- 2019-03-01 US US16/290,496 patent/US10441661B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN03009A (en:Method) | ||
| MY153046A (en) | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | |
| IN2012DN02661A (en:Method) | ||
| MY162499A (en) | Methylphenidate-prodrugs, processes of making and using the same | |
| HK1203309A1 (zh) | 抗體-藥物綴合物以及相關化合物、組合物和方法 | |
| NZ746440A (en) | Glycinamide derivatives and production methods thereof | |
| EP4592275A3 (en) | Hydrazinyl-pyrrolo compounds and methods for producing a conjugate | |
| MX2012001665A (es) | Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos. | |
| WO2012054748A3 (en) | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway | |
| EP2449114A4 (en) | NEW LIPID FORMULATIONS FOR THE DELIVERY OF THERAPY AGENTS IN SOLID TUMORS | |
| MX2010009670A (es) | Conjugados de paclitaxel polimericos y metodos para tratamiento de cancer. | |
| SG10201805198TA (en) | 18f - fluciclovine compositions in citrate buffers | |
| PH12017500963A1 (en) | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxycodone | |
| AR083150A1 (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona | |
| EP2813515A4 (en) | PROCESS FOR PREPARING A TRANSDERLY APPLIED HYALURONIC ACID PROTEIN CONJUGATE AND TRANSDERMALLY APPLIED HYALURONIC ACID PROTEIN CONJUGATE THEREOF | |
| MY162934A (en) | Anticancer steroidal lactones unsaturated in position 7 (8) | |
| PH12012501552A1 (en) | Therapeutic or prophylactic agent for biliary diseases | |
| PH12017500859A1 (en) | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of oxymorphone, prodrugs, methods and making and use thereof | |
| MX2010001084A (es) | Tratamiento de tumores pediatricos. | |
| GB2509476A (en) | 18F - Fluciclovine compositions in citrate buffers | |
| NZ593849A (en) | Methods to treat cancer | |
| MX2010004332A (es) | Esteres de camptotecina cristalinos hidratados para el tratamiento de cancer. | |
| UA112329C2 (uk) | Композиція проліків, що містить кон'югат аспірину з гідроморфоном, та спосіб лікування захворювання | |
| HK1207561A1 (en) | Compositions and methods for treating hepatocellular cancer | |
| NZ594996A (en) | Cholestanol derivative for combined use |